Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association
10.12779/dnd.2022.21.2.45
- Author:
Kee Hyung PARK
1
;
Jae-Won JANG
;
Jeewon SUH
;
SangHak YI
;
Jae-Sung BAE
;
Jae-Sung LIM
;
Hyon LEE
;
Juhee CHIN
;
Young Ho PARK
;
Yun Jeong HONG
;
Geon Ha KIM
;
On behalf of Academic Committee of the Korean Dementia Association
Author Information
1. Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- Publication Type:Review Article
- From:Dementia and Neurocognitive Disorders
2022;21(2):45-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.
